News | April 07, 2025
Dr Reddy’s Laboratories gets Rs 2,395 crore show cause notice from IT authority
Dr Reddy’s said scheme of amalgamation was carried with adherence to all the legal requirements including tax laws
Dr Reddy’s said scheme of amalgamation was carried with adherence to all the legal requirements including tax laws
Bio-Thera will maintain responsibility for development, manufacturing, and supply of BAT2206 and BAT2506
The revenue from operations in Q3 FY25 is Rs. 8,358.6 crore, up 16% YoY
The total covered market size of four brands – Z&D, Pediclory, Pecef & Ezinapi combined is Rs 1800 crores
The integration and transition of the brands are expected to be completed by June 2022.
He has extensive leadership experience across supply chain and has worked at companies such as Unilever, Flipkart, Colgate-Palmolive & Mondelez
The entire integration and transition of the brands is expected to be completed by March 2022
The Vasostrict brand market had U.S. sales of approximately US $ 878.5 million MAT for the most recent twelve months ending in December 2021 according to IQVIA Health
ICICI Direct analysis of Dr Reddy’s Q3FY22 results
Dr. Reddy's Laboratories has reported consolidated financial results for the period ended December 31, 2021
Subscribe To Our Newsletter & Stay Updated
